Currently Viewing:
Newsroom
Currently Reading
Pfizer Announces Phase 3 Trial for Atopic Dermatitis Treatment
December 15, 2017 – Samantha DiGrande
Majority of Women With Breast Cancer Surgery Did Not Feel Fully Informed of Treatment Options
December 15, 2017 – Jaime Rosenberg
AJMC® in the Press, December 15, 2017
December 15, 2017 – AJMC Staff
What We're Reading: Medicare Lab Testing; CHIP Deadline; AMA Expands Diabetes Efforts
December 15, 2017 – AJMC Staff
5 Key Takeaways From ASH 2017
December 15, 2017 – Surabhi Dangi-Garimella, PhD
This Week in Managed Care: December 15, 2017
December 15, 2017
What We're Reading: Medical Device Tax; Marijuana and Vaping; Birth Control Without Prescriptions
December 14, 2017 – AJMC Staff
Study Finds Breathing Retraining Associated With Quality of Life Improvement for Patients With Asthma
December 14, 2017 – Laura Joszt
Rain and Pain Not Related, Harvard Researchers Say
December 13, 2017 – Allison Inserro

Updates to Treatment Options During Breast Cancer Awareness Month

Surabhi Dangi-Garimella, PhD
October is breast cancer awareness month, and as September ended, a new treatment received the FDAs approval for advanced breast cancer and another was granted priority review for the adjuvant treatment of early breast cancer.
October is breast cancer awareness month, and as September ended, a new treatment received the FDA’s approval for advanced breast cancer and another was granted priority review for the adjuvant treatment of early breast cancer.

On September 28, the FDA approved abemaciclib (Verzenio) for the treatment of adult patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced or metastatic breast cancer that has progressed on endocrine therapy. A CDK4/6 inhibitor, abemaciclib is currently approved in combination with fulvestrant in patients who have progressed on endocrine therapy. It is also approved to be given alone in combination with endocrine therapy and chemotherapy following metastasis.

Abemaciclib was evaluated in combination with fulvestrant in a randomized trial of 669 patients with HR-positive, HER2-negative breast cancer that had progressed following treatment with endocrine therapy and who had not received chemotherapy following metastasis. Median progression-free survival was 16.4 months in the abemaciclib plus chemotherapy arm, compared with 9.4 months in patients treated with a placebo and chemotherapy.

Abemaciclib as a stand-alone was evaluated in a single-arm study in 132 patients with HR-positive, HER2-negative breast cancer that had progressed on endocrine therapy and chemotherapy following metastasis. Nearly 20% of patients on abemaciclib presented with partial or complete shrinkage of their tumors for a median period of 8.6 months.

On September 29, Roche announced that the FDA had accepted a supplemental Biologics License Application (sBLA) for pertuzumab (Perjeta) in combination with trastuzumab (Herceptin) and chemotherapy for adjuvant treatment of HER2-positive early breast cancer. While the FDA has already granted an accelerated approval for the combination, the current submission is aimed at converting it to a full approval.

The decision date for the sBLA is January 28, 2018.  

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!